Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FILANA THERAPEUTICS, INC.SAVA · Entity 7294 | Chief Clinical Dev. Officer | November 18, 2024 | November 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FILANA THERAPEUTICS, INC.
Report date November 18, 2024 · Filed November 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.95 · Expires 2034-11-18 | Direct | 85,000 |
Reported balance
After 2024-11-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-11-18 · Grant · Acquired 85,000 · Balance 85,000 F1: The stock option vests in four equal annual installments (25% each year) with the initial 25% vesting on November 18, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in four equal annual installments (25% each year) with the initial 25% vesting on November 18, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 18, 2024 Filed Nov 20, 2024 21:39 UTC | FILANA THERAPEUTICS, INC. SAVA · Entity 7294 | GrantStock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $27.95 | $0.00 |
DisclosureSEC source: 0001437749-24-035872 · rdgdoc.xml · derivative · entry 1 Landen Jaren · CIK 0002045287 · Chief Clinical Dev. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2034-11-18 F1 · derivative.exercise_date: The stock option vests in four equal annual installments (25% each year) with the initial 25% vesting on November 18, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.